A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

ClinicalTrials.gov ID: NCT03246529

Public ClinicalTrials.gov record NCT03246529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study

Study identification

NCT ID: NCT03246529
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: BioLineRx, Ltd.; Industry
Enrollment: 180 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

BL-8040 1.25 mg/kg + G-CSF Drug
Placebo +G-CSF Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 78 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 22, 2018
Primary completion: Dec 21, 2020
Completion: Sep 29, 2029
Last update posted: Jan 14, 2026

2018 – 2029

United States locations

U.S. sites: 10
U.S. states: 9
U.S. cities: 10

Facility	City	State	ZIP	Site status
UCLA Medical Center	Los Angeles	California	167817	—
University of Florida	Gainesville	Florida	100278	—
University of Miami	Miami	Florida	33136	—
Loyola University Medical Center	Chicago	Illinois	60611	—
University of Maryland	Baltimore	Maryland	21201	—
Mayo Clinic	Rochester	Minnesota	55902	—
The Washington University School of Medicine	St Louis	Missouri	63110	—
University of Cincinnati	Cincinnati	Ohio	45221	—
MD Anderson Cancer Center	Houston Texas	Texas	77030	—
Huntsman Cancer Institute in University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03246529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 14, 2026 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03246529 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →